Management of Left Ventricular Thrombus
Diagnostic Approach
- The American College of Cardiology recommends transesophageal echocardiography (TEE) as the preferred imaging modality to visualize LV thrombus, including its size, location, and mobility 2
Treatment Algorithm
- The American College of Cardiology recommends beginning immediate anticoagulation with intravenous unfractionated heparin (target aPTT >2 times control) for patients with confirmed LV thrombus 2
- The American Heart Association recommends transitioning to oral anticoagulation with warfarin (target INR 2.5-3.5) for patients with confirmed LV thrombus 1
- The American College of Cardiology recommends adding low-dose aspirin (81-100 mg/day) if no contraindications exist for patients with confirmed LV thrombus 2
- The American Heart Association recommends continuing anticoagulation for a minimum of 3 months for patients with confirmed LV thrombus 1
- The American College of Cardiology recommends considering extended therapy in patients with large or mobile thrombi 2
Special Situations
- The American College of Cardiology recommends considering thrombolytic therapy followed by heparin, then warfarin plus aspirin for high surgical risk patients (NYHA class III-IV) with prosthetic valve thrombosis 2
- The American Heart Association recommends warfarin for at least 3 months for patients with ischemic stroke or TIA and LV thrombus 1
Follow-up
- The American College of Cardiology recommends performing serial echocardiography every 1-3 months to assess for thrombus resolution 2
- The American College of Cardiology recommends considering surgical intervention if thrombus persists despite adequate anticoagulation after 3-6 months 2
Emerging Evidence on Direct Oral Anticoagulants (DOACs)
- The American Heart Association found that one study comparing DOACs to warfarin found higher rates of stroke or systemic embolism in the DOAC group 1
Common Pitfalls and Caveats
- The American College of Cardiology found that inadequate anticoagulation intensity (subtherapeutic INR) is associated with treatment failure and increased thromboembolic risk 2